Select Page
Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained on this website is not a comprehensive list. While we make reasonable efforts to present current and accurate information on this website, this website could include inaccuracies or typographical errors. We do not guarantee and are not responsible for the quality, currency, propriety, accuracy, or reasonableness of any information on this website. Please contact info@canceraction.ca with any inquiries about the terms of use.

Brand NameGeneric NameManufacturerTumour SiteIndicationRoute of AdministrationInformation Source
MasivetmasitinibAB ScienceGastrointestinalMetastatic pancreatic cancerOralhttp://www.ab-science.com/pipeline/masitinib
MasivetmasitinibAB ScienceGenitourinaryMetastatic Castrate Resistant Prostate Cancer in first lineOralhttp://www.ab-science.com/pipeline/masitinib
VenclextavenetoclaxAbbVieLeukemiaAcute Myeloid Leukemia (AML)Oralhttps://www.abbvie.com/our-science/pipeline.html
VenclextavenetoclaxAbbVieMyelomaMultiple myelomaOralhttps://www.abbvie.com/our-science/pipeline.html
veliparibAbbVieLungOvarian cancerOralhttps://www.abbvie.com/our-science/pipeline.html
veliparibAbbVieBreastBreast cancerOralhttps://www.abbvie.com/our-science/pipeline.html
veliparibAbbVieLungLung cancerOralhttps://www.abbvie.com/our-science/pipeline.html
Rova-Trovalpituzumab tesirineAbbVieLungSmall cell lung cancer, first lineIntravenoushttps://www.abbvie.com/our-science/pipeline.html
ImbruvicaibrutinibAbbVieLymphomaFollicular lymphomaOralhttps://www.abbvie.com/our-science/pipeline.html
EmplicitielotuzumabAbbVieMyelomaMultiple myeloma treatment naïveIntravenoushttps://www.abbvie.com/our-science/pipeline.html
EmplicitielotuzumabAbbVieMyelomaMultiple myeloma second lineIntravenoushttps://www.abbvie.com/our-science/pipeline.html
depatuxizumab mafodotinAbbVieNeurologicalGlioblastoma MultiformeIntravenoushttps://www.abbvie.com/our-science/pipeline.html
Imlygictalimogene laherparepvecAmgenMelanomaUnresected metastatic melanomaSubcutaneoushttp://www.amgentrials.com/amgen/studysearch.aspx?SearchStr=talimogene+laherparepvec
XgevadenosumabAmgenOtherAdults and skeletally-mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to reult in severe morbiditySubcutaneoushttp://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
KyproliscarfilzomibAmgenMyelomaMultiple myeloma, in combination with chemotherapyIntravenoushttp://www.amgenpipeline.com/pipeline/
BlincytoblinatumomabAmgenLymphomaDiffuse large B cell lymphoma (DLBCL)Intravenoushttp://www.amgenpipeline.com/pipeline/
Braftovi + Mektoviencorafenib + binimetinibPfizerMelanomametastatic melanoma, BRAF-mutant Oralhttps://www.pfizer.com/science/drug-product-pipeline
Braftovi + Mektoviencorafenib + binimetinibPfizerGastrointestinalcolorectal cancer, BRAF-mutant Oralhttps://www.pfizer.com/science/drug-product-pipeline
zolbetuximab (IMAB362)Astellas PharmaGastrointestinalGastroesophageal adenocarcinomaIntravenoushttps://www.astellas.com/jp/en/investors/ir-library/pipeline
XospatagilteritinibAstellas PharmaLeukemiaAcute myeloid leukemiaOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm627045.htm
enfortumab vetodinAstellas PharmaGenitourinaryUrothelial cancerIntravenoushttps://www.astellas.com/jp/en/investors/ir-library/pipeline
savolitinibAstraZenecaGenitourinaryPapillary renal cell carcinomaoralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
TagrissoosimertinibAstraZenecaLungAdjuvant EGRFm NSCLCOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaGenitourinaryProstate cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaGynecologyFirst line BRCAm ovarian cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaBreastmBRCA adjuvant breast cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LynparzaolaparibAstraZenecaGastrointestinalPancreatic cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
Lumoxitimoxetumomab pasudotoxAstraZenecaLeukemiaHairy cell leukaemiaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm620473.htm
durvalumab + tremelimumabAstraZenecaGastrointestinalGastric cancerIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaGastrointestinalMetastatic pancreatic ductal carcinomaIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaGastrointestinalHepatocellular carcinomaIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaLung3rd-line NSCLCIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaLung1st-line NSCLCIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaGenitourinary1st-line bladder cancerIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaHead and Neck2nd-line SCCHNIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaHead and Neck1st-line SCCHNIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
cediranibAstraZenecaGynecologyRecurrent platinum resistant ovarian cancerOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
AZD6738AstraZenecaGastrointestinalGastric cancer, in combination with olaparibhttps://www.astrazeneca.com/our-focus-areas/oncology.html
capivasertibAstraZenecaBreastBreast canceroralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
CalquenceacalabrutinibAstraZenecaLymphomaB-cell malignancyOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
CalquenceacalabrutinibAstraZenecaLeukemiaFirst-line chronic lymphocytic leukemiaOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
CalquenceacalabrutinibAstraZenecaLeukemiaRelapsed/refractory chronic lymphocytic leukemia and high riskOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
CalquenceacalabrutinibAstraZenecaLeukemiaFirst-line mantle cell lymphomaOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
NubeqadarolutamideBayerGenitourinarynon metastatic castration-resistant prostate cancerIntravenoushttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-darolutamide-non-metastatic-castration-resistant-prostate-cancer
NubeqadarolutamideBayerGenitourinaryhormone sensitive prostate cancerIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
AliqopacopanlisibBayerLymphomaNon Hodgkin LymphomaIntravenoushttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
AliqopacopanlisibBayerLymphomarelapsed follicular lymphomaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm576098.htm
xenituzumabBoehringer IngelheimBreastMetastatic breast cancerhttps://www.inoncology.com/our-compounds
VargatefnintedanibBoehringer IngelheimLungAdvanced non‑small cell lung cancer Oralhttps://www.inoncology.com/our-compounds
GiotrifafatinibBoehringer IngelheimLungSquamous Non-Small Cell Lung Cancer Oralhttps://www.inoncology.com/our-compounds
OpdivonivolumabBristol-Myers SquibbGastrointestinalmismatch repair deficient (dMMR) and microsatellite instability high (MSI-H) metastatic colorectal cancerIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569366.htm
IstodaxromidepsinCelgeneLymphomaFirst-line peripheral T-cell lymphomaIntravenoushttps://www.celgene.com/research-development/
IstodaxromidepsinCelgeneLymphomaCutaneous T-cell lymphomaIntravenoushttps://www.celgene.com/research-development/
CC-486CelgeneOtherLower-risk myelodysplastic syndromeOralhttps://www.celgene.com/research-development/
Abraxanenab-paclitaxelCelgeneGastrointestinalAdjuvant therapy for pancreatic cancerIntravenoushttps://www.celgene.com/research-development/
marizomibCelgeneNeurologicalGlioblastoma multiformehttps://www.celgene.com/research-development/
luspaterceptCelgeneOtherMyleodysplastic syndromeSubcutaneoushttps://www.celgene.com/research-development/
RevlimidlenalidomideCelgeneLymphomaFirst-line diffuse large B-cell lymphoma (ABC-subtype)Oralhttps://www.celgene.com/research-development/
RevlimidlenalidomideCelgeneLymphomaRelapsed/refractory indolent lymphomaOralhttps://www.celgene.com/research-development/
RevlimidlenalidomideCelgeneLymphomaFirst-line follicular lymphomaOralhttps://www.celgene.com/research-development/
RevlimidlenalidomideCelgeneLymphomaMantle cell lymphoma (relapsed/refractory)Oralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm355438.htm
CC-486CelgeneLeukemiaPost-induction acute myeloid leukemia maintenanceIntravenoushttps://www.celgene.com/research-development/
RubracarucaparibClovis OncologyGynecologyDeleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapiesOralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm533891.htm
MORAb-004EisaiMelanomaMelanomaIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
LenvimalenvatinibEisaiGastrointestinalBiliary tract cancerOralhttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
LenvimalenvatinibEisaiGenitourinaryFirst-line renal cell carcinomaOralhttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
farletuzumabEisaiGynecologyPlatinum-sensitive ovarian cancerIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
HalaveneribulinEisaiGenitourinaryUnresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.Intravenous https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm483795.htm
HalaveneribulinEisaiBreastTriple negative Breast cancerIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
amatuximabEisaiLungMesotheliomaIntravenoushttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
CyramzaramucirumabEli LillyGastrointestinalMetastatic colorectal cancer, in combination with Folfiri, for patients whose disease has progressed on a first line bevacizumab, oxaliplatin, and fluoropyrimidine-containing regimenIntravenoushttp://wayback.archive-it.org/7993/20170111231635/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm444496.htm
CyramzaramucirumabEli LillyGastrointestinalGastric cancerIntravenoushttp://lillyoncologypipeline.com/clinical-phase/II
CyramzaramucirumabEli LillyGastrointestinalHepatocellular carcinoma, second-line treatment Intravenoushttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ramucirumab-hepatocellular-carcinoma
CyramzaramucirumabEli LillyLungMetastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy, in combination with docetaxelIntravenoushttp://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm426735.htm
necitumumabEli LillyLungSquamous non-small cell lung cancerIntravenoushttp://lillyoncologypipeline.com/assets/cms/molecule_flashcards/pipeline_brochure.pdf
merestinibEli LillyGastrointestinalFirst-line advanced or metastatic biliary tract cancerOralhttp://lillyoncologypipeline.com/assets/cms/molecule_flashcards/pipeline_brochure.pdf
VerzenioabemaciclibEli LillyGenitourinaryProstate cancerOralhttp://lillyoncologypipeline.com/assets/cms/molecule_flashcards/pipeline_brochure.pdf
VerzenioabemaciclibEli LillyLungSquamous non-small cell lung cancerOralhttp://lillyoncologypipeline.com/assets/cms/molecule_flashcards/pipeline_brochure.pdf
VerzenioabemaciclibEli LillyBreastPostmenopausal women with hormone-receptor-positive, HER2-negative locoregionally recurrent or metastatic breast cancer, with anastrozole or fulvestrantOralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
tepotinibEMD SeronoGastrointestinalHepatocellular cancerOralhttps://www.emdgroup.com/en/research/biopharma-pipeline.html?_ga=2.1945463.75812796.1559521939-1503451630.1517146188
tepotinibEMD SeronoLungNon-small cell lung cancerOralhttps://www.emdgroup.com/en/research/biopharma-pipeline.html?_ga=2.1945463.75812796.1559521939-1503451630.1517146188
BavencioavelumabEMD SeronoGastrointestinalGastric cancer, first lineIntravenoushttps://www.emdgroup.com/en/research/biopharma-pipeline.html?_ga=2.1945463.75812796.1559521939-1503451630.1517146188
BavencioavelumabEMD SeronoHead and NeckLocally advanced head and neckIntravenoushttps://www.emdgroup.com/en/research/biopharma-pipeline.html?_ga=2.1945463.75812796.1559521939-1503451630.1517146188
BavencioavelumabEMD SeronoLungNon-small cell lung cancerIntravenoushttps://www.emdgroup.com/en/research/biopharma-pipeline.html?_ga=2.1945463.75812796.1559521939-1503451630.1517146188
BavencioavelumabEMD SeronoGenitourinaryRenal cell carcinoma, first lineIntravenoushttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avelumab-plus-axitinib-renal-cell-carcinoma
CometriqcabozantinibExelixisGastrointestinalColorectal cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
BavencioavelumabEMD SeronoGenitourinaryUrothelial cancer. first lineIntravenoushttps://www.emdgroup.com/en/research/biopharma-pipeline.html?_ga=2.1945463.75812796.1559521939-1503451630.1517146188
CometriqcabozantinibExelixisGastrointestinalHepatocellular cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisSarcomaSoft tissue sarcomaOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisBreastBreast cancer patients with brain metastases, with trastuzumabOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisBreastMetastatic, hormone-receptor positive breast cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisLungNon-small cell lung cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisGynecologyEndometrial cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisSarcomaHigh grade uterine sarcomaOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisSarcomaRelapsed osteosarcoma or Ewing sarcomasOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisEndocrineDifferentiated thyroid cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisGenitourinaryRenal cell cancer, first lineOralhttps://www.exelixis.com/cabozantinib-development-program/
ZelborafvemurafenibGenentechEndocrinePapillary thyroid cancer, BRAF mutation positiveOralhttps://www.gene.com/medical-professionals/pipeline
CometriqcabozantinibExelixisGenitourinaryBladder cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisBreastTriple negative breast cancer, with nivolumabOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisGastrointestinalMetastatic pancreatic cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisNeurologicalNeuroendocrine and carcinoid tumorsOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisGastrointestinalMetastatic gastrointestinal stromal tumorOralhttps://www.exelixis.com/cabozantinib-development-program/
ErivedgevismodegibGenentechOtherOperable basal cell carcinomaOralhttps://www.gene.com/medical-professionals/pipeline
Kadcylatrastuzumab emtansineGenentechBreast1st line HER2-positive metastatic breast cancerIntravenoushttps://www.gene.com/medical-professionals/pipeline
Kadcylatrastuzumab emtansineGenentechBreast3rd line HER2-positive metastatic breast cancerIntravenoushttps://www.gene.com/medical-professionals/pipeline
polatuzumab vedotinGenentechLymphomaNon-Hodgkin's lymphoma and diffuse large B-cell lymphomaIntravenoushttps://www.gene.com/medical-professionals/pipeline
PerjetapertuzumabGenentechBreastEarly HER2-positive breast cancerIntravenoushttps://www.gene.com/medical-professionals/pipeline
GazyvaobinutuzumabGenentechLymphomaDiffuse large B-cell lymphomaIntravenoushttps://www.gene.com/medical-professionals/pipeline
GazyvaobinutuzumabGenentechLymphomaRefractory indolent non-Hodgkin's lymphomaIntravenoushttps://www.gene.com/medical-professionals/pipeline
ipatasertibGenentechGastrointestinalGastric cancerOralhttps://www.gene.com/medical-professionals/pipeline
ipatasertibGenentechBreastHR+ or Triple-negative breast cancerOralhttps://www.gene.com/medical-professionals/pipeline
ipatasertibGenentechGastrointestinalProstate cancerOralhttps://www.gene.com/medical-professionals/pipeline
TecentriqatezolizumabGenentechGenitourinaryFor locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chem or have disease progression within 12 mo's of neoadjuvant or adjuvant treatment with platinum-containing chemoIntravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501878.htm
VenclextavenetoclaxHoffmann-La RocheLeukemiamyelodysplastic syndromes, first-line treatment, in combination with azacitidineOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheMyelomaRelapsed or refractory multiple myelomaOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheLymphomaFront-line diffuse large B-cell lymphomaOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheLeukemiaAcute myelogenous leukemia, first-line treatmentOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm626499.htm
Kadcylatrastuzumab emtansineHoffmann-La RocheBreastEarly HER2-positive breast cancer, adjuvant treatment, in combination with PerjetaIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Kadcylatrastuzumab emtansineHoffmann-La RocheBreastEarly HER2-positive breast cancer, adjuvant treatmentIntravenoushttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ado-trastuzumab-emtansine-early-breast-cancer
Polivypolatuzumab vedotinHoffmann-La RocheLeukemiaFirst line Diffuse Large B-cell LymphomaIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
pertuzumab FDC SCHoffmann-La RocheBreastEarly breast cancer, in combination with HerceptinIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
ipatasertibHoffmann-La RocheBreastTriple-negative breast cancer, neo-adjuvant treatmentOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
ipatasertibHoffmann-La RocheBreastTriple-negative breast cancer, first-line treatmentOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
ipatasertibHoffmann-La RocheGenitourinaryCastration-resistant prostate cancerOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
idasanutlinHoffmann-La RocheLeukemiaAcute myeloid leukemiaOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Cotellic + Tecentriq + Zelborafcobimetinib + atezolizumab + vemurafenibHoffmann-La RocheMelanomaBRAFv600 mutation-positive advanced melanoma, first-line treatmentOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
CotelliccobimetinibHoffmann-La RocheBreastFirst line metastatic triple negative breast cancerOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGynecologyOvarian cancer, front-line treatmentIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinarymetastatic urothelial cancerIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
DarzalexdaratumumabJanssenMyelomain combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantIntravenoushttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-multiple-myeloma-ineligible-autologous-stem-cell-transplant
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous and squamous non-small cell lung cancer, PDL1-selected patientsIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryRenal cell cancer, in combination with AvastinIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous non-small cell lung cancer, in combination with chemotherapy, with or without AvastinIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm627874.htm
TecentriqatezolizumabHoffmann-La RocheLungNon-small cell lung cancer, adjuvant treatmentIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line squamous non-small cell lung cancer, combination regimen with chemotherapyIntravenous
TecentriqatezolizumabHoffmann-La RocheGenitourinaryMuscle-invasive bladder cancer, adjuvant treatmentIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryFirst-line metastatic urothelial carcinomaIntravenous
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous non-small cell lung cancer, in combination with chemotherapy and pemetrexedIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst line extensive-stage small cell lung cancerIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm633814.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryRenal cell carcinoma, adjuvant treatmentIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheBreastMetastatic triple-negative breast cancer, first-line treatmentIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryCastration-resistant prostate cancerIntravenous
ImbruvicaibrutinibJanssenLeukemiaFrontline chronic lymphocytic leukemia, in combination with obinutuzumabOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLeukemiaFrontline chronic lymphocytic leukemia (young and fit), in combinaction with rituximabOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLymphomaTreatment naive patients with mantle cell lymphoma, in combination with Bendamustine and RituximabOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLymphomaRelapsed/refractory indolent non-Hodgkin's lymphoma, in combination with bendamustine and rituximab or R-CHOPOralhttp://www.janssen.com/research-and-development/product-pipeline
ImbruvicaibrutinibJanssenLymphomaRelapsed/refractory patients with Mantle Cell Lymphoma (MCL) in combination with venetoclaxOralhttp://www.janssen.com/research-and-development/product-pipeline
DarzalexdaratumumabJanssenMyelomaFrontline multiple myeloma transplant-ineligible patientsIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
DarzalexdaratumumabJanssenMyeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant (ASCT)Intravenoushttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-transplant-eligible-multiple-myeloma
apalutamide + abiraterone acetateJanssenGenitourinaryMetastatic castration-resistant chemotherapy-naïve prostate cancerOralhttp://www.janssen.com/research-and-development/product-pipeline
apalutamideJanssenGenitourinarymetastatic castration-sensitive prostate cancer (mCSPC)Oralhttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-apalutamide-metastatic-castration-sensitive-prostate-cancer
apalutamideJanssenGenitourinaryLocalized prostate cancerOralhttp://www.janssen.com/research-and-development/product-pipeline
ZytigaabirateroneJanssenGenitourinaryNewly Diagnosed Hormone Naïve Metastatic Prostate Cancer Oralhttp://www.janssen.com/research-and-development/product-pipeline
Vyxeosliposome-encapsulated combination of daunorubicin and cytarabine Jazz PharmaceuticalLeukemianewly diagnosed high risk AMLIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569950.htm
KeytrudapembrolizumabMerckGastrointestinalEsophogeal cancerIntravenoushttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-advanced-esophageal-squamous-cell-cancer
KeytrudapembrolizumabMerckGastrointestinalrecurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 Intravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm577093.htm
KeytrudapembrolizumabMerckGastrointestinalColorectal CancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGastrointestinalLiver cancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGynecologyOvarian CancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckBreastBreast cancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckGenitourinaryplus axitinib for the first-line treatment of advanced renal cell carcinomaIntravenoushttps://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-plus-axitinib-advanced-renal-cell-carcinoma
KeytrudapembrolizumabMerckGenitourinaryProstate cancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckHead and NeckNasopharyngeal cancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckHead and NeckRecurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapyIntravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm515627.htm
OdomzosonidegibNovartisOtherlocally advanced basal cell carcinomaOralhttp://wayback.archive-it.org/7993/20170111231633/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm455865.htm
FarydakpanobinostatNovartisMyelomaMultiple myeloma, in combination with bortezomib and dexamethasone, for patients who have received at least two prior regimens including bortezomib and an immunomodulatory agentOralhttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm435339.htm
ArzerraofatumumabNovartisLeukemiaFor extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL)Intravenoushttp://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
EGF816NovartisLungNon-small cell lung cancerOralhttps://www.novartis.com/our-company/novartis-oncology
capmatinibNovartisLungNon-small cell lung cancerOralhttps://www.novartis.com/our-company/novartis-oncology
PiqrayalpelisibNovartisBreastin combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancerOralhttps://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications
TalzennatalazoparibPfizerBreastGermline BRCA-mutated metastatic breast cancerOralhttps://www.pfizer.com/science/drug-product-pipeline
SutentsunitinibPfizerGenitourinaryadjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm585686.htm
IbrancepalbociclibPfizerBreastHigh-risk early breast cancerOralhttps://www.pfizer.com/science/drug-product-pipeline
IbrancepalbociclibPfizerBreastEarly breast cancer in adjuvant settingOralhttps://www.pfizer.com/science/drug-product-pipeline
DaurismoglasdegibPfizerLeukemiaAcute Myeloid Leukemia (AML)Oralhttps://www.pfizer.com/science/drug-product-pipeline
Mylotarggemtuzumab ozogamicinPfizerLeukemiaAcute Myeloid LeukemiaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm574518.htm
XalkoricrizotinibPfizerLungROS1-positive metastatic non-small cell lung cancerOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm490391.htm
BosulifbosutinibPfizerLeukemiaChronic myelogenous leukemia, first lineOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm589856.htm
BavencioavelumabPfizerHead and NeckLocally Advanced Squamous Cell Carcinoma of the Head and NeckIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGenitourinaryUrothelial Carcinoma, first lineIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerLungNon small cell lung cancer, first lineIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
BavencioavelumabPfizerGastrointestinalGastric cancer, first lineIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
NerlynxneratinibPuma Biotechnology Inc.Breastfor the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm567259.htm
LibtayocemiplimabSanofiSkinAdvanced cutaneous squamous cell carcinomaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm622251.htm
LibtayocemiplimabSanofiSkinAdvanced basal cell carcinomaIntravenoushttps://www.sanofigenzyme.com/en/products-research/research-pipeline
LibtayocemiplimabSanofiLungNSCLC, first lineIntravenoushttps://www.sanofigenzyme.com/en/products-research/research-pipeline
isatuximabSanofiMeylomaMultiple myeloma, newly diagnosed, relapsed or refractoryIntravenoushttps://www.sanofigenzyme.com/en/products-research/research-pipeline
tisotumab vetodinSeattle GeneticsGenitourinaryrecurrent Cervical cancerIntravenoushttp://www.seattlegenetics.com/pipeline
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaFrontline Hodgkin lymphoma in patients 60+, in combination with niovlumabIntravenoushttp://www.seattlegenetics.com/pipeline
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaSecond-line Hodgkin lymphoma, in combination with nivolumabIntravenoushttp://www.seattlegenetics.com/pipeline
BavencioavelumabEMD SeronoOtherMerkel cell carcinoma, first lineIntravenoushttps://www.emdgroup.com/en/research/biopharma-pipeline.html?_ga=2.1945463.75812796.1559521939-1503451630.1517146188
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaRelapsed Classical Hodgkin lymphoma, in combination with niovlumabIntravenoushttp://www.seattlegenetics.com/pipeline
ZejulaniraparibTesaro, Inc.Gynecologymaintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm548487.htm
Yescartaaxicabtagene ciloleucel Gilead SciencesLymphomaindolent NHLIntravenoushttp://www.gilead.com/research/pipeline
YescartaAxicabtagene ciloleucel Kite PharmaceuticalsLymphomarelapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphomaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm581296.htm
CabometyxcabozantinibIpsen PharmaGenitourinaryRenal cell carcinoma, first lineOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm589842.htm
CabometyxcabozantinibExelixisGastrointestinalHepatocellular carcinoma, second line after sorafenibOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm629512.htm
VerzenioabemaciclibEli LillyBreastHigh-Risk, Node-Positive, Early-Stage, Hormone-Receptor-Positive, HER 2-Negative Breast Cancer, adjuvant therapyOralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
XtandienzalutamidePfizerGenitourinaryNon-metastatic hormone sensitive, high risk, prostate cancerOralhttps://www.pfizer.com/science/drug-product-pipeline
LibtayocemiplimabSanofiGynecologyCervical cancerIntravenoushttps://www.sanofigenzyme.com/en/products-research/research-pipeline
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomaprimary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapyIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm584543.htm
pevonedistatTakedaLeukemiaHigh risk MDSIntravenoushttps://www.takeda.com/siteassets/system/what-we-do/research-and-development-rd-in-takeda/our-pipeline/pipeline_en_q4.pdf
TAK-659TakedaLymphomaNon Hodgkin LymphomaOralhttps://www.takeda.com/siteassets/system/what-we-do/research-and-development-rd-in-takeda/our-pipeline/pipeline_en_q4.pdf
KTE-X19Gilead SciencesLymphomaMCLIntravenoushttp://www.gilead.com/research/pipeline
CalquenceacalabrutinibAstraZenecaLeukemiaMantle cell lymphoma, after at least one prior therapyOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm583106.htm
asciminib (ABL001)NovartisLeukemiaChronic Myeloid LeukemiaOralhttps://www.novartis.com/our-company/novartis-oncology
ladiratuzumab vedotinSeattle GeneticsBreastHER2-negative breast cancerIntravenoushttp://www.seattlegenetics.com/pipeline
enfortumab vedotin Seattle GeneticsGenitourinarymetastatic urothelial cancer post PD-L1 inhibitorIntravenoushttp://www.seattlegenetics.com/pipeline
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomapreviously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapyIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm601947.htm
TecentriqatezolizumabHoffmann-La RocheBreastAdjuvant triple-negative breast cancerIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
GazyvaobinutuzumabGenentechLymphomaFront-line indolent non-Hodgkin's lymphomaIntravenoushttps://www.gene.com/medical-professionals/pipeline
ZytigaabirateroneJanssenGenitourinaryin combination with prednisone for metastatic high-risk castration-sensitive prostate cancerOralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm596015.htm
TalzennatalazoparibPfizerGenitourinaryMetastatic castration-resistant prostate cancerOralhttps://www.pfizer.com/science/drug-product-pipeline
Onivydeirinotecan liposomeIpsen PharmaGastrointestinalPancreatic ductal adenocarcinomab (PDAC)Intravenoushttps://www.ipsen.com/research-development/pipeline/
Onivydeirinotecan liposomeIpsen PharmaLungSmall Cell Lung cancer (SCLC), second lineIntravenoushttps://www.ipsen.com/research-development/pipeline/
KeytrudapembrolizumabMerckLungSmall Cell Lung cancer (SCLC)Intravenoushttps://www.merck.com/research/pipeline/home.html
LynparzaolaparibMerckGastrointestinalPancreatic cancerOralhttps://www.merck.com/research/pipeline/home.html
LynparzaolaparibMerckGenitourinaryProstate cancerOralhttps://www.merck.com/research/pipeline/home.html
isatuximabSanofiLeukemiaPediatric AML and ALLIntravenoushttps://www.sanofigenzyme.com/en/products-research/research-pipeline
BlincytoblinatumomabAmgenLeukemia B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission Intravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm603171.htm
telisotuzumab vedotinAbbVieLungNon-small cell lung cancerIntravenoushttps://www.abbvie.com/our-science/pipeline.html
Imfinzi + Lynparzadurvalumab + olaparibAstraZenecaGenitourinary1st-line unresectable stage IV bladder cancerhttps://www.astrazeneca.com/our-focus-areas/oncology.html
selumetinibAstraZenecaNeurologicalpediatric neurofibromastosis type 1https://www.astrazeneca.com/our-focus-areas/oncology.html
tislelizumabCelgeneLungNon-small cell lung cancerIntravenoushttps://www.celgene.com/research-development/
Liso-cel, JCAR017CelgeneLymphomaLarge B-Cell LymphomaIntravenoushttps://www.celgene.com/research-development/
LenvimalenvatinibEisaiGynecologicalendometrial carcinomaoralhttps://www.fda.gov/drugs/resources-information-approved-drugs/simultaneous-review-decisions-pembrolizumab-plus-lenvatinib-australia-canada-and-us
LartruvoolaratumabEli LillySarcomaAdvanced Soft Tissue Sarcoma, in combination with gemcitabine and docetaxelIntravenoushttp://lillyoncologypipeline.com/assets/cms/molecule_flashcards/pipeline_brochure.pdf
pegilodecakinEli LillyGastrointestinalPancreatic cancerSubcutaneoushttp://lillyoncologypipeline.com/assets/cms/molecule_flashcards/pipeline_brochure.pdf
pegilodecakinEli LillyLungNon-small cell lung cancerSubcutaneoushttp://lillyoncologypipeline.com/assets/cms/molecule_flashcards/pipeline_brochure.pdf
abituzumabEMD SeronoGastrointestinalColorectal CancerOralhttps://www.emdgroup.com/en/research/biopharma-pipeline.html?_ga=2.1945463.75812796.1559521939-1503451630.1517146188
entrectinibGenentechLungNon-small cell lung canceroralhttps://www.gene.com/medical-professionals/pipeline
tiragolumabGenentechLungNon-small cell lung cancerIntravenoushttps://www.gene.com/medical-professionals/pipeline
Polivypolatuzumab vedotinHoffmann-La RocheLymphomarelapsed/refractory Follicular lymphomaIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
CometriqcabozantinibExelixisGenitourinaryProstate cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisGynecologyOvarian cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisMyelomaMultiple myeloma, in combination with carfilzomibOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisHead and NeckSquamous cell carcinoma of the head and neckOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisNeurologicalNeurofibromasOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisNeurologicalpediatriac gliomaOralhttps://www.exelixis.com/cabozantinib-development-program/
AlecensaalectinibHoffmann-La RocheLungALK+ non-small cell lung cancer, adjuvantOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
CabometyxcabozantinibIpsen PharmaGenitourinaryRenal cell carcinoma, first line in combination with nivolumabOralhttps://www.ipsen.com/research-development/pipeline/
DarzalexdaratumumabJanssenMyelomaSmoldering multiple myelomaIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
DarzalexdaratumumabJanssenMyelomaRelapsed/refractory multiple myeloma, in combination with pomalidomideIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
KeytrudapembrolizumabMerckSkinCutaneous squamous cell carcinomaIntravenoushttps://www.merck.com/research/pipeline/home.html
LenvimalenvatinibMerckGastrointestinalBiliary tract canceroralhttps://www.merck.com/research/pipeline/home.html
LenvimalenvatinibMerckLungNon-small cell lung canceroralhttps://www.merck.com/research/pipeline/home.html
Cavatakcoxsackievirus, CVA21MerckMelanomaMelanomaIntratumoralhttps://www.merck.com/research/pipeline/home.html
IlariscanakinumabNovartisLungNon-small cell lung cancerSubcutaneoushttps://www.novartis.com/our-company/novartis-oncology
IlariscanakinumabNovartisLungNon-small cell lung cancer, adjuvant treatmentSubcutaneoushttps://www.novartis.com/our-company/novartis-oncology
ArzerraofatumumabNovartisLymphomaRefractory indolent non-Hodgkin's lymphomaIntravenoushttps://www.novartis.com/our-company/novartis-oncology
KymriahtisagenlecleucelNovartisLeukemiaChronic lymphocytic leukemiaIntravenoushttps://www.novartis.com/our-company/novartis-oncology
KymriahtisagenlecleucelNovartisLymphomaRelapsed/refractory diffuse large B-cell lymphomaIntravenoushttps://www.novartis.com/our-company/novartis-oncology
KymriahtisagenlecleucelNovartislymphomaRelapsed/refractory follicular lymphomaIntravenoushttps://www.novartis.com/our-company/novartis-oncology
KisqaliribociclibNovartisBreastBreast cancer, adjuvantOralhttps://www.novartis.com/our-company/novartis-oncology
KisqaliribociclibNovartisBreastBreast cancer, pre-menopausal womenOralhttps://www.novartis.com/our-company/novartis-oncology
spartalizumabNovartisMelanomaMetastatic melanomaIntravenoushttps://www.novartis.com/our-company/novartis-oncology
spartalizumabNovartisMelanomaMetastatic melanoma with dabrafenib/trametinibIntravenoushttps://www.novartis.com/our-company/novartis-oncology
RydaptmidostaurinNovartisLeukemiaAcute myeloid leukemia, FLT3 wild typeOralhttps://www.novartis.com/our-company/novartis-oncology
BavencioavelumabPfizerSkinMerkel Cell Carcinoma, first lineIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
IbrancepalbociclibPfizerBreastER+, HER2+ breast cancerOralhttps://www.pfizer.com/science/drug-product-pipeline
isatuximab + cemiplimabSanofiMeylomaRelapsed refractory multiple myelomaIntravenoushttps://www.sanofigenzyme.com/en/products-research/research-pipeline
tucatinibSeattle GeneticsBreastHER2 positive Breast canceroralhttp://www.seattlegenetics.com/pipeline
TAK-931TakedaLungSquamous Non-small cell lung cancerhttps://www.takeda.com/siteassets/system/what-we-do/research-and-development-rd-in-takeda/our-pipeline/pipeline_en_q4.pdf
MyovantrelugolixTakedaGenitourinaryprostate cancerhttps://www.takeda.com/siteassets/system/what-we-do/research-and-development-rd-in-takeda/our-pipeline/pipeline_en_q4.pdf
Tafinlar + Mekinistdabrafenib + trametinibNovartisEndocrineanaplastic thyroid cancerhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm606708.htm
KeytrudapembrolizumabMerckGynecologicalrecurrent or metastatic cervical cancerintravenouhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610572.htm
AvastinbevacizumabGenentechGynecologyepithelial ovarian, fallopian tube, or primary peritoneal cancer intravenouhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610664.htm
TibsovoivosidenibAngios PharmaceuticalsLeukemiaacute myeloid leukemiaoralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm614128.htm
Azedraiobenguane I 131 Progenics Pharmaceuticalspheochromocytoma or paraganglioma (PPGL) intravenouhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm615157.htm
OpdivonivolumabBristol-Myers SquibbLungmetastatic small cell lung cancerintravenouhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617370.htm
CopiktraduvelisibVerastem IncLeukemiachronic lymphocytic leukemiaoralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621503.htm
Talzennatalazoparib PfizerGenitourinaryMetastatic castration-resistant prostate cancer first line, in combination with enzalutamideoralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm623540.htm
KeytrudapembrolizumabMerckLungmetastatic squamous non-Small Cell Lung cancer, first lineIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm625705.htm
Adcetrisbrentuximab vedotinSeattle GeneticsLymphomasystemic anaplastic large cell lymphoma (sALCL) or CD30-expressing periperal T-cell lymphomaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm584543.htm
rogaratinibBayerGenitourinaryurothelial canceroralhttp://pharma.bayer.com/en/innovation-partnering/development-pipeline/
ElzonristagraxofuspStemline TherapeuticsNeurologicalblastic plasmacytoid dendritic cell neoplasm (BPDCN)intravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm629090.htm
Asparlascalaspargase pegol-mnkServier Pharmaceuticals LeukemiaAcute myeloid leukemiaintravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm628980.htm
IdasanutlinGenentechLeukemiaAcute myeloid leukemia, relapsed/refractoryoralhttps://www.gene.com/medical-professionals/pipeline
DarzalexdaratumumabJanssenMyelomaRelapsed/refractory multiple myeloma, in combination with carfilzomibIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
KeytrudapembrolizumabMerckSkinMerkel cell carcinomaIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm628867.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinarynon-muscle invasive bladder cancerIntravenous
TecentriqatezolizumabHoffmann-La RocheGastrointestinalHepatocellular carcinomaIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheGenitourinaryRenal cell carcinoma, adjuvant therapyIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheLungFirst-line non-squamous non-small cell lung cancer diagnostic positive via blood based TMB assayIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheBreasttriple-negative breast cancer, neo-adjuvant treatmentIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
TecentriqatezolizumabHoffmann-La RocheBreastHER2 positive breast cancer, neo-adjuvant treatmentIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxAbbVieLeukemiaChronic lymphocytic leukemia (CLL), first lineOralhttps://www.abbvie.com/our-science/pipeline.html
VenclextavenetoclaxAbbVieLeukemiaMyelodysplatic SyndromeOralhttps://www.abbvie.com/our-science/pipeline.html
CalquenceacalabrutinibAstraZenecaLeukemiarelapsed/refractory mantle cell lymphomaOralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
LenvimalenvatinibEisaiGastrointestinalHepatocellular carcinoma, first-lineOralhttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
LenvimalenvatinibEisaiGastrointestinalMelanomaOralhttp://www.eisai.com/pdf/eir/erepo/epipeline.pdf
bintrafusp alfaEMD SeronoLungNon-small cell lung cancerIntravenoushttps://www.emdgroup.com/en/research/biopharma-pipeline.html?_ga=2.1945463.75812796.1559521939-1503451630.1517146188
CometriqcabozantinibExelixisSarcomapediatriac sarcomaOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisEndocrineMetastatic Adrenocortical CarcinomaOralhttps://www.exelixis.com/cabozantinib-development-program/
CometriqcabozantinibExelixisGastrointestinalrefractory metastatic colorectal cancerOralhttps://www.exelixis.com/cabozantinib-development-program/
KTE-X19Gilead SciencesLymphomaALLIntravenoushttp://www.gilead.com/research/pipeline
VenclextavenetoclaxHoffmann-La RocheBreastHR+ breast cancer, second lineOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
VenclextavenetoclaxHoffmann-La RocheLeukemiaAcute myelogenous leukemia, first-line treatment in combination with LDACOralhttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Polivypolatuzumab vedotinHoffmann-La RocheLymphomain combination with bendamustine and a rituximab product for relapsed/refractory diffuse large B-cell lymphoma (DLBCL)Intravenoushttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-polatuzumab-vedotin-piiq-diffuse-large-b-cell-lymphoma
tucatinibSeattle GeneticsBreastBreast cancer, neoadjuvantoralhttp://www.seattlegenetics.com/pipeline
KeytrudapembrolizumabMerckGastrointestinalGastric CancerIntravenoushttps://www.merck.com/research/pipeline/home.html
KeytrudapembrolizumabMerckLungMesotheliomaIntravenoushttps://www.merck.com/research/pipeline/home.html
isatuximab + cemiplimabSanofiLymphomaLymphomaIntravenoushttps://www.sanofigenzyme.com/en/products-research/research-pipeline
BavencioavelumabPfizerGynecologySolid Tumors with a BRCA or ATM defect, in combination with talazoparibIntravenoushttps://www.pfizer.com/science/drug-product-pipeline
TecentriqatezolizumabHoffmann-La RocheBreastPD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancerIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm633065.htm
Herceptin Hylectatrastuzumab and hyaluronidase-oysk GenentechBreastHER2 overexpressing breast cancerSubcutaneoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm632294.htm
Lonsurftrifluridine - tipiracilTaihoGastrointestinal metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated oralhttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm632032.htm
KeytrudapembrolizumabMerckSkinadjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resectionIntravenoushttps://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm631565.htm
Braftovi + Mektoviencorafenib + binimetinibPfizerLungNSCLC, BRAF-mutant , first lineOralhttps://www.pfizer.com/science/drug-product-pipeline
oleclumabAstraZenecaGastrointestinalmetastatic pancreatic cancerIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
trastuzumab deruxtecanAstraZenecaGastrointestinalHER2 expressing advanced colorectal cancerIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
trastuzumab deruxtecanAstraZenecaLungHER2 over expressing or mutated metastatic non small cell lung cancerIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
adavosertibAstraZenecaGynecologyOvarian canceroralhttps://www.astrazeneca.com/our-focus-areas/oncology.html
durvalumab + tremelimumabAstraZenecaGastrointestinalBiliary tract cancerIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
trastuzumab deruxtecanAstraZenecaBreastHERr2 positive breast cancerIntravenoushttps://www.astrazeneca.com/our-focus-areas/oncology.html
bb2121 (BCMA CAR-T)CelgeneMyelomarelapsed/refractory multiple myelomaintravenoushttps://www.celgene.com/research-development/
LartruvoolaratumabEli LillyGastrointestinalPancreatic cancerintravenoushttp://lillyoncologypipeline.com/assets/cms/molecule_flashcards/pipeline_brochure.pdf
bintrafusp alfaEMD SeronoGastrointestinalBiliary tract cancerIntravenoushttps://www.emdgroup.com/en/research/biopharma-pipeline.html?_ga=2.1945463.75812796.1559521939-1503451630.1517146188
sapanisertibTakedaGynecologyEndometrial cancerOralhttps://www.takeda.com/siteassets/system/what-we-do/research-and-development-rd-in-takeda/our-pipeline/pipeline_en_q4.pdf
TAK-788TakedaLungNon-small cell lung canceroralhttps://www.takeda.com/siteassets/system/what-we-do/research-and-development-rd-in-takeda/our-pipeline/pipeline_en_q4.pdf
KeytrudapembrolizumabMerckLungfirst-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation or metastatic NSCLCIntravenoushttps://www.fda.gov/drugs/fda-expands-pembrolizumab-indication-first-line-treatment-nsclc-tps-1
RevlimidlenalidomideCelgeneLymphomain combination with a rituximab product for previously treated follicular lymphoma (FL) and marginal zone lymphoma (MZL)Oralhttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lenalidomide-follicular-and-marginal-zone-lymphoma
Yescartaaxicabtagene ciloleucel Gilead SciencesLymphomaDLBCLIntravenoushttp://www.gilead.com/research/pipeline
Individualised Neoantigen-Specific Therapy, iNeST (RG6180)Hoffmann-La RocheSkinMelanomaIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
CabometyxcabozantinibIpsen PharmaGastrointestinalhepatic cellular carcinoma, first line in combination with atezolizumaboralhttps://www.ipsen.com/research-development/pipeline/
niraparibJanssenGenitourinaryprostate canceroralhttp://www.janssen.com/research-and-development/product-pipeline
BCMA CAR-TJanssenMyelomaMultiple myelomaIntravenoushttp://www.janssen.com/research-and-development/product-pipeline
LorbrenalorlatinibPfizerLungALK non-small cell lung cancer, first lineOralhttps://www.pfizer.com/science/drug-product-pipeline
ladiratuzumab vedotinSeattle GeneticsBreastTriple negative breast cancer (with pembrolizumab or atezolizumabIntravenoushttp://www.seattlegenetics.com/pipeline
XpovioselinexorKaryopharm TherapeuticsMyelomain combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibodyOralhttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-selinexor-multiple-myeloma
KeytrudapembrolizumabMerckLungMetastatic Small Cell Lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapyIntravenoushttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-metastatic-small-cell-lung-cancer
KeytrudapembrolizumabMerckHead and Neckfirst-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC)Intravenoushttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-first-line-treatment-head-and-neck-squamous-cell-carcinoma
KeytrudapembrolizumabMerckGastrointestinalAdvanced esophageal cancerIntravenoushttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-advanced-esophageal-squamous-cell-cancer
TeraliopexidartinibDaichi SankoOthertenosynovial giant cell tumor Oralhttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pexidartinib-tenosynovial-giant-cell-tumor
RozlytekentrectinibGenentechOthersolid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusionoralhttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc
isatuximab + atezolizumabSanofiGastrointestinalmetastatic colorectal cancerIntravenoushttps://www.sanofigenzyme.com/en/products-research/research-pipeline
niraparibTesaro, Inc.Gynecologyadvanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive statusOralhttps://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer
tucatinibSeattle GeneticsGastrointestinalColorectal cancer (+ trastuzumab)oralhttp://www.seattlegenetics.com/pipeline
capmatinibNovartisLungNSCLCOralhttps://www.novartis.com/our-company/novartis-oncology
TecentriqatezolizumabHoffmann-La RocheHead and Neckadjuvant SCCHNIntravenoushttps://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm